OVERVIEW

Cortagen 20 mg (Bioregulator) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Pro (AEDP) that falls into a class of bioregulatory peptides studied in laboratory and preclinical research for its potential effects on the central nervous system and cellular gene regulation. It is derived conceptually from components originally identified in brain extracts and is explored for its ability to modulate gene expression, neuronal signalling, oxidative stress responses, and neuroplasticity in controlled experimental models. Researchers use Cortagen to investigate mechanisms linked to synaptic function, neuronal survival, inflammation balance, and metabolic signalling in neural tissue, often evaluating outcomes such as transcriptional changes, cellular stress markers, and protective effects under models of neural injury. Some studies also evaluate its influence in peripheral tissues such as immune or cardiac cells within laboratory systems.

Despite scientific interest in its biological mechanisms, Cortagen is not approved for therapeutic use by the U.S. Food and Drug Administration or other major regulatory bodies, and it is typically supplied strictly for research use only. This means its safety, efficacy, dosing, and long-term effects in humans have not been established, and products bearing this peptide are not manufactured to pharmaceutical standards. Purity, quality, and experimental outcomes can vary between sources, and it is not intended for human or veterinary consumption. Any exploration of Cortagen’s effects should remain confined to qualified laboratory settings under appropriate oversight rather than self-administration.